Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
RNF4 sustains Myc-driven tumorigenesis by facilitating DNA replication
Joonyoung Her, … , Haiyan Zheng, Samuel F. Bunting
Joonyoung Her, … , Haiyan Zheng, Samuel F. Bunting
Published March 26, 2024
Citation Information: J Clin Invest. 2024;134(10):e167419. https://doi.org/10.1172/JCI167419.
View: Text | PDF
Research Article Genetics Oncology

RNF4 sustains Myc-driven tumorigenesis by facilitating DNA replication

  • Text
  • PDF
Abstract

The mammalian SUMO-targeted E3 ubiquitin ligase Rnf4 has been reported to act as a regulator of DNA repair, but the importance of RNF4 as a tumor suppressor has not been tested. Using a conditional-knockout mouse model, we deleted Rnf4 in the B cell lineage to test the importance of RNF4 for growth of somatic cells. Although Rnf4–conditional-knockout B cells exhibited substantial genomic instability, Rnf4 deletion caused no increase in tumor susceptibility. In contrast, Rnf4 deletion extended the healthy lifespan of mice expressing an oncogenic c-myc transgene. Rnf4 activity is essential for normal DNA replication, and in its absence, there was a failure in ATR-CHK1 signaling of replication stress. Factors that normally mediate replication fork stability, including members of the Fanconi anemia gene family and the helicases PIF1 and RECQL5, showed reduced accumulation at replication forks in the absence of RNF4. RNF4 deficiency also resulted in an accumulation of hyper-SUMOylated proteins in chromatin, including members of the SMC5/6 complex, which contributes to replication failure by a mechanism dependent on RAD51. These findings indicate that RNF4, which shows increased expression in multiple human tumor types, is a potential target for anticancer therapy, especially in tumors expressing c-myc.

Authors

Joonyoung Her, Haiyan Zheng, Samuel F. Bunting

×

Figure 6

RNF4 deficiency extends tumor-free lifespan of Eμ-myc–transgenic mice.

Options: View larger image (or click on image) Download as PowerPoint
RNF4 deficiency extends tumor-free lifespan of Eμ-myc–transgenic mice.
(...
(A) Tumor-free survival of Rnf4+/+ CD19-Cre or Rnf4fl/+ CD19-Cre (n = 38), and Rnf4fl/fl CD19-Cre (n = 44). (B) Tumor-free survival of Rnf4+/+ Trp53+/– CD19-Cre or Rnf4fl/+ Trp53+/– CD19-Cre (n = 30), and Rnf4fl/fl Trp53+/– CD19-Cre (n = 30). (C) Tumor-free survival of Eμ-myc Rnf4+/+ CD19-Cre or Eμ-myc Rnf4fl/+ CD19-Cre (n = 47), and Eμ-myc Rnf4fl/fl CD19-Cre (n = 27). (D) Analysis of chromosome aberrations of B cells of the indicated genotypes after 2 days in culture. (E) Analysis of cell viability of B cells of the indicated genotypes during 72 hours of in vitro growth. (F) Growth of U2OS-iMYC cells after doxycycline-induced expression of c-myc, measured by quantification of CellTiter-Glo fluorescence. P values show difference between the means of unstimulated and stimulated cells. (G) Analysis of replication fork velocity measured by DNA combing. Total CldU plus IdU tract length is shown. Mean ± SD of n = 3 experiments shown. (H) Intensity of γ-H2AX staining in S-phase (EdU+) cells. (I) Survival of pediatric B cell acute lymphoblastic leukemia patients with tumors expressing either normal or increased levels of RNF4. (J) Model for steps leading to cell death in RNF4-deficient cells. Absence of RNF4 activity causes increased abundance of SUMOylated proteins in chromatin, leading to replication stress and accumulation of nonproductive intermediates, dependent on RAD51, which prevents successful completion of DNA replication and further cell proliferation. Error bars in D–F and H show SD of the mean. P values were calculated by log-rank test (A–C and I), unpaired 2-tailed t test (D and F), 2-way ANOVA with Dunnett’s multiple-comparison test (E), and 1-way ANOVA with Tukey’s multiple-comparison test (G and H). P < 0.05 was considered statistically significant. *P < 0.05; **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts